Evidence map›Paper›PMID 22558197›Full record

ArticlePloS one2012

Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease.

Yazi D Ke, Yazi Ke, Joe Dramiga, Ulrich Schütz, Jillian J Kril, Lars M Ittner, Hannsjörg Schröder, Jürgen Götz

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 107 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Tau Isoforms: Gaining Insight intoInternational journal of molecular sciences · 2022
    Review
  11. Article
  12. Familial ALS-associatedOpen biology · 2022
    Article
  13. Article
  14. RNA Dynamics in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2021
    Review
  15. Article
  16. Article
  17. Altered ribosomal function and protein synthesis caused by tau.Acta neuropathologica communications · 2021
    Article
  18. Review
  19. Article
  20. Alternative splicing in Alzheimer's disease.Aging clinical and experimental research · 2021
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Ke, Yazi [corrected to Ke, Yazi D]
5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yazi D KeAlzheimer's and Parkinson's Disease Laboratory, Brain & Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia.
Yazi Ke
Joe Dramiga
Ulrich Schütz
Jillian J Kril
Lars M Ittner
Hannsjörg Schröder
Jürgen Götz
University of Sydney · AUUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tau dysfunction characterizes neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). Here, we performed an unbiased SAGE (serial analysis of gene expression) of differentially expressed mRNAs in the amygdala of transgenic pR5 mice that express human tau carrying the P301L mutation previously identified in familial cases of FTLD. SAGE identified 29 deregulated transcripts including Sfpq that encodes a nuclear factor implicated in the splicing and regulation of gene expression. To assess the relevance for human disease we analyzed brains from AD, Pick's disease (PiD, a form of FTLD), and control cases. Strikingly, in AD and PiD, both dementias with a tau pathology, affected brain areas showed a virtually complete nuclear depletion of SFPQ in both neurons and astrocytes, along with cytoplasmic accumulation. Accordingly, neurons harboring either AD tangles or Pick bodies were also depleted of SFPQ. Immunoblot analysis of human entorhinal cortex samples revealed reduced SFPQ levels with advanced Braak stages suggesting that the SFPQ pathology may progress together with the tau pathology in AD. To determine a causal role for tau, we stably expressed both wild-type and P301L human tau in human SH-SY5Y neuroblastoma cells, an established cell culture model of tau pathology. The cells were differentiated by two independent methods, mitomycin C-mediated cell cycle arrest or neuronal differentiation with retinoic acid. Confocal microscopy revealed that SFPQ was confined to nuclei in non-transfected wild-type cells, whereas in wild-type and P301L tau over-expressing cells, irrespective of the differentiation method, it formed aggregates in the cytoplasm, suggesting that pathogenic tau drives SFPQ pathology in post-mitotic cells. Our findings add SFPQ to a growing list of transcription factors with an altered nucleo-cytoplasmic distribution under neurodegenerative conditions.

Indexed as

Alzheimer DiseaseAmygdalaAnimalsAstrocytesCell DifferentiationCell Line, TumorCytoplasmDown-RegulationEntorhinal CortexFrontotemporal Lobar DegenerationGene Expression ProfilingHumansMaleMiceMice, TransgenicMitomycinMitomycinPTB-Associated Splicing FactorRNA-Binding Proteinstau ProteinsTretinoin

Identifiers

PMID22558197
PMCPMC3338448
OpenAlexW2085199754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.